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Case Report

Adrenalectomy for solitary metastasis of Hepatocellular carcinoma
post liver transplantation: Case report and literature review
Imran Khan Jalbani1, Syed M Nazim2,
Muhammad Usman Tariq3, Farahat Abbas4
ABSTRACT
Liver transplantation (LT) is the treatment of choice for localized hepatocellular carcinoma (HCC) associated
with cirrhosis. Extra hepatic metastasis is the most common cause of death in these patients. There is very
little evidence regarding the natural history and treatment options for patients developing HCC recurrence
after LT. Surgical resection offers a unique opportunity for solitary metastasis. We report a 61 year old male
with solitary right adrenal metastasis 15 months post LT which was managed with open adrenalectomy.
The patient is alive and disease free 24 months after the surgery. The case, histo-pathological findings and
literature review is discussed.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the most
common tumor of liver parenchyma and the
fifth most common cancer in the world.1 The
epidemiological distribution of HCC varies across
the globe being the highest in south East Asia and
sub-Saharan Africa.2 Chronic liver disease (CLD)
and HCC are the consequences of viral hepatitis
and nearly 17 million in people in Pakistan are
affected by viral hepatitis.3
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Liver transplantation (LT) is treatment of choice
for CLD and localized hepatocellular carcinoma.4
The commonest cause of death in patients with HCC
is extra-hepatic metastasis which is usually multifocal.5 Surgical resection offers a unique opportunity
for solitary metastasis after LT.5 To our knowledge
solitary adrenal metastasis is a rare finding and the
available data is limited to few case reports and
there is no consensus on its management. Herein,
we report a case of right adrenal metastasis of HCC
fifteen month post LT, patients is alive and doing
well 24 months after adrenalectomy.
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A 61-year-old gentleman with controlled diabetes
mellitus and 13 years history of hepatitis C and
chronic liver disease underwent live non related
LT in October 2012 in China for hepatocellular
carcinoma lesion measuring 3.5cm on preoperative
imaging. The pre-operative serum alpha fetoprotein
(AFP) values were within normal limits. Final
histopathology of resected liver showed a focus of
hepatocellular carcinoma grade II, with tumor size
of 3 cm without any major vascular involvement.
He did not receive any pre or post-transplant

Hepatocellular carcinoma post liver transplantation

chemotherapy. Immunosuppressant treatment
comprised of FK506 2.5mg and mycophenolate
mofetil (Celcept) 750mg twice daily
Unfortunately, the patient did not follow a
standardized surveillance protocol and was referred
to us fifteen months post LT with an ultrasound
scan revealing a right adrenal mass with normal
serum AFP (1.0 IU/ml). He denied any history of
weight loss, abdominal pain or hyper adrenergic
symptoms. Contrast enhanced computerized
tomography (CT) of chest and abdomen showed
normal transplanted liver and an enhancing right
adrenal mass with central necrosis measuring
30 x 33 x 55 mm without any evidence of distant
disease (Fig.1). A positron emission tomography
(PET) scan confirmed the hyper metabolic lesion,
raising suspicion of malignancy with standardized
uptake value (SUV) of 4.5. The metabolic workup was negative for pheochromocytoma, Cushing
syndrome and Conn’s syndrome.
He underwent a right open adrenalectomy
in March 2014 through right flank incision and
histopathology revealed metastatic HCC with
angio-lymphatic invasion (Fig.2). The patient made
good recovery and was discharged. However he
was advised to switch to Everolimus from FK506
as it decreases chances of HCC recurrence. After
almost 39 months post-transplant he is doing well
and under close surveillance.

sis and has shown to improve the overall survival.4
A careful follow up is needed in these patients due
to possibility of recurrence not only in the graft
but also in extra-hepatic organs.1 The recurrence of
HCC after liver transplant is reported to be as high
as 10%, with studies reporting most of extra hepatic
recurrence within first year of transplant.6,7
There is very little evidence in literature regarding the natural history, effects of medical or surgical treatment and predictors of survival in patients
who develop HCC recurrence after LT. Management of single site metastasis of HCC after LT lacks
the consensus but certainly depends on various
factors like, site, size of tumor, tumor resectability,
patient’s functional status, comorbid medical conditions, biochemical markers (AFP) and presence or
absence of HCC in the transplanted liver.8
In clinical practice, adrenal gland is an uncommon
site of metastasis from HCC with incidence ranging
from 1- 2.4%. Few autopsy reports have showed
that it is the second site of hematogenous spread
from HCC after lung, with reported incidence of
8.4%.9
The experience of surgical excision (adrenalectomy) for metastasis is limited to mainly case reports
and these lesions can also be managed with other
non-surgical modalities. Combined Radiofrequency ablation (RFA) with trans-arterial chemoemboli-

DISCUSSION
Liver transplantation (LT) is currently the best
available option for select cases of HCC with cirrho-

Fig.1: Axial images of contrast enhanced CT, showing
normal transplanted liver, spleen, left kidney and right
adrenal mass abutting liver (arrow).

Fig.2: A: Tumour cells infiltrating into the normal
adrenal gland parenchyma at the periphery H&E, 100
xM). B: Large lobules of neoplastic cells surrounded by
rich sinusoidal network. Intracytoplasmic eosinophilic
inclusions are also seen in large size, polygonal cells
(H&E, 400 x M). C: Tumor cells (Right) staining positive
for Cytokeratin CAM5.2 immunohistochemical stain
while normal adrenal tissue (Left) are negative (200xM).
D: Diffuse Hep-par1 positive immunohistochemical stain
membranes and cytoplasmic (left) while normal adrenal
tissue (right) is negative (H&E, 400 xM).
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zation (TACE) was described in a series from Japan
for adrenal metastasis from HCC and showed it to
be a safe option which can lengthen survival.9
In an analysis of 30 patients who had adrenal
metastasis from HCC, Park JS et al.10 reported adrenalectomy in five patients, non-surgical treatment
such as TACE or chemo + radiation therapy in 19
patients. Six patients did not receive any treatment.
They reported a median survival of 11 months.
They also observed that the incidence of metastasis is higher on the right adrenal gland compared
to left side. They concluded that adrenalectomy for
metastatic HCC results in improved patient survival especially those in good general condition.
In a recently published study from Korea, Ha
TY et al.11 studied 26 patients with metachronous
adrenal metastasis in patients who underwent
liver resection (19 patients) or LT (7 patients). All
patients had adrenal recurrence within 18 months
and underwent adrenalectomy. The mean diameter
of tumor was 3.4±1.8 cm in LT group. The five year
survival after adrenalectomy was 20.3%.Our case
was found to have HCC of resected liver following
transplantation and had metachronous adrenal
metastasis 15 months post LT which was managed
successfully by surgical excision.
Recurrence after LT does reduce overall survival.
Several factors have been identified that contribute
to increased recurrence and affect the survival.
These include >1 tumor, size > 5 cm and recurrence
within one year.9
Uka K et al.12 reported a cumulative survival rate
of 21.7%, 14.2% and 7.1% respectively one, two and
three years after the initial diagnosis of extra hepatic
metastasis in patients with HCC with a median survival of 4.9 months (range, 0-37 months). Roayaie S
et al. in their series have shown that patients who
undergo resection or ablation of a recurrence had
that.8
Serum AFP is a good indicator for HCC
metastasis.7 Our case was unique in that it had
normal serum AFP levels both before the LT and
after adrenal metastatic despite of considerable
sized tumor. The patient is presently alive and
disease free. He is under regular surveillance with
CT /PET scan along with tumor marker.
CONCLUSION
We believe that surgical excision (adrenalectomy)
should be considered for selected LT patients
with solitary adrenal metastasis from HCC.
Further evidence is needed to develop definite
recommendations.
1046 Pak J Med Sci 2016 Vol. 32 No. 4

www.pjms.com.pk

Declaration of interest: The authors declare
that there is no conflict of interest regarding the
publication.
REFERENCES
1.

Mittal S, El-Serag HB. Epidemiology of hepatocellular
carcinoma: consider the population. J Clin Gastroenterol.
2013;47(Suppl):S2-6. DOI: 10.1097/MCG.0b013e3182872f29
2. Hamid AS, Tesfamariam IG, Zhang Y, Zhang ZG. Aflatoxin
B1-induced hepatocellular carcinoma in developing
countries: Geographical distribution, mechanism of action
and prevention. Oncol Lett. 2013;5(4):1087-1092. doi:
10.3892/ol.2013.1169
3. Idrees M, Rafique S, Rehman I, Akbar H, Yousaf MZ,
Butt S, et al. Hepatitis C virus genotype 3a infection and
hepatocellular carcinoma: Pakistan experience. World J
Gastroenterol. 2009;15(40):5080–5085.
4. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A,
Bozzetti F, et al. Liver transplantation for the treatment of
small hepatocellular carcinomas in patients with cirrhosis.
N Engl J Med. 1996;334(11):693-699.
5. Rubio E, Gonzalez J, Jimenez M, Lucena JL, Gimenez
L, Martinez Arrieta F, et al. Right adrenal metastases of
hepatocarcinoma after liver transplantation: case report and
literature review. Transplant Proc. 2009;41(3):1067-1069.
DOI: 10.1016/j.transproceed.2009.02.018
6. Chen SW, Wang S, Wang B, Li WD, Yan S, Xie LP.
Metachronous pulmonary and adrenal metastases after
liver transplantation for hepatocarcinoma. World J Surg
Oncol. 2011;9(1):156. DOI: 10.1186/1477-7819-9-156.
7. Perez-Saborido B, de los Galanes SJ, Meneu-Diaz JC,
Romero CJ, Elola-Olaso AM, Suarez YF, et al. Tumor
recurrence after liver transplantation for hepatocellular
carcinoma: recurrence pathway and prognostic factors.
Transplant Proc. 2007;39(7):2304-2307. DOI:10.1016/j.
transproceed.2007.06.059
8. Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM,
Gondolesi GE, et al. Recurrence of hepatocellular carcinoma
after liver transplant: patterns and prognosis. Liver Transpl.
2004;10(4):534-540. DOI: 10.1002/lt.20128
9. Yamakado K, Anai H, Takaki H, Sakaguchi H, Tanaka T,
Kichikawa K, et al. Adrenal metastasis from hepatocellular
carcinoma: radiofrequency ablation combined with adrenal
arterial chemoembolization in six patients. Am J Roentgenol.
2009;192(6):W300-305. doi: 10.2214/AJR.08.1752.
10. Park JS, Yoon DS, Kim KS, Choi JS, Lee WJ, Chi HS, et al.
What is the best treatment modality for adrenal metastasis
from hepatocellular carcinoma? J Surg Oncol. 2007;96 (1):3236. doi: 10.1002/jso.20773
11. Ha TY, Hwang S, Ahn CS, Kim KH, Lee YJ, Moon DB,
et al. Resection of Metachronous Adrenal Metastasis
after
Liver
Resection
and
Transplantation
for
Hepatocellular Carcinoma. Dig Surg. 2015;31(6):428-435.
doi:10.1159/000370078
12. Uka K, Aikata H, Takaki S, Shirakawa H, Jeong SC,
Yamashina K, et al. Clinical features and prognosis of
patients with extrahepatic metastases from hepatocellular
carcinoma. World J Gastroenterol. 2007,13(3):414-420. doi:
10.3748/wjg.v13.i3.414

